SCHEDULE: SilverArc Capital Management Discloses NextCure Stake

SilverArc Capital Management, LLC and Devesh Gandhi have reported beneficial ownership of 4.9% of NextCure, Inc.'s Class A Common Stock as of March 31, 2026.

Summary

• SilverArc Capital Management, LLC and Devesh Gandhi (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating their beneficial ownership of NextCure, Inc. Class A Common Stock.
• As of March 31, 2026, the Reporting Persons collectively beneficially owned 176,057 shares of NextCure's Class A Common Stock.
• This ownership represents 4.9% of the total class of securities.
• The filing indicates shared voting and dispositive power over these shares.
• SilverArc Capital Management, LLC is a Delaware limited liability company, and Devesh Gandhi is a U.S. citizen.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on ownership and does not contain performance data or strategic announcements that would strongly influence sentiment.

Positives

• Reporting Persons hold a significant stake (4.9%) in NextCure, Inc., which could indicate confidence in the company's future prospects.
• The filing is made in accordance with standard regulatory requirements, suggesting transparency in ownership.

Negatives

• The ownership stake is just below the 5% threshold that would trigger more extensive disclosure requirements, potentially limiting the insight into the Reporting Persons' intentions.
• No specific strategic plans or intentions beyond ordinary course of business are detailed in this filing.

Risks

• The filing does not explicitly detail risks, but the concentration of ownership by a single entity could pose a risk if that entity decides to divest its holdings.
• As a Schedule 13G filing, it implies the ownership is passive, but any shift in strategy by the Reporting Persons could impact the company.

Future Outlook

The filing does not contain forward-looking statements or specific guidance regarding future performance. It primarily reports on current ownership status.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant stakeholders who acquire substantial stakes in public companies. This filing indicates SilverArc Capital Management's interest in NextCure, Inc., a biotechnology company, aligning with broader investment trends in the healthcare and life sciences sectors.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant ownership block, which can influence market perception. The passive nature of the filing suggests no immediate intent to control or disrupt.
• Management and Board: Awareness of a substantial passive investor may inform strategic discussions and governance considerations.

Next Steps

• Continued monitoring of NextCure, Inc. by SilverArc Capital Management, LLC and Devesh Gandhi.
• Potential for future filings if ownership levels change significantly or if the nature of the investment shifts from passive to active.

Key Dates

Keywords

NextCure, Schedule 13G, SilverArc Capital Management, Devesh Gandhi, Beneficial Ownership, Common Stock, SEC Filing, Investment